Gene therapy for peripheral arterial disease

Expert Opinion on Biological Therapy

Volumn 14, Issue 8, 2014, Pages 1175-1184

  Shimamura, Munehisa ^a   Nakagami, Hironori ^a   Taniyama, Yoshiaki ^b   Morishita, Ryuichi ^b  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Cell based therapy; Fibroblast growth factor; Gene therapy; Hepatocyte growth factor; VEGF

Indexed keywords

FIBROBLAST GROWTH FACTOR; PLASMID DNA; PROSTACYCLIN SYNTHASE; SCATTER FACTOR; VASCULOTROPIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; CELL THERAPY; GENE THERAPY; GENE TRANSFER; MICROBUBBLE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); GENETICS; HUMAN; ISCHEMIA; LEG; PERIPHERAL ARTERIAL DISEASE; PROCEDURES; VASCULARIZATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; FIBROBLAST GROWTH FACTORS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HEPATOCYTE GROWTH FACTOR; HUMANS; ISCHEMIA; LOWER EXTREMITY; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL ARTERIAL DISEASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904003930     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.912272     Document Type: Review

References (77)

1. European Working Group on Critical Limb Ischaemia, American Heart Association. Second European Consensus Document on chronic critical leg ischemia. Circulation 1991;84:IV1-26
2. Check E. Gene therapy: Shining hopes dented-but not dashed. Nature 2002;420:735 (Pubitemid 36019597)
3. Dormandy J, Mahir M, Ascady G, et al. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino) 1998;30:50-7
4. Rutherford RB, Flanigan DP, Gupta SK, et al. Suggested standards for reports dealing with lower extremity ischemia. Prepared by the ad hoc committee on reporting standards, society for vascular surgery/north american chapter, international society for cardiovascular surgery. J Vasc Surg 1986;4:80-94
5. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999;286:2244-5 (Pubitemid 30016842)
6. Lee RJ, Springer ML, Blanco-Bose WE, et al. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression. Circulation 2000;102:898-901
7. Springer ML, Chen AS, Kraft PE, et al. VEGF gene delivery to muscle: Potential role for vasculogenesis in adults. Mol Cell 1998;2:549-58 (Pubitemid 128379081)
8. Rajagopalan S, Shah M, Luciano A, et al. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 2001;104:753-5 (Pubitemid 32762670)
9. Mäkinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: A randomized, placebocontrolled, double-blinded phase II study. Mol Ther 2002;6:127-33 (Pubitemid 36124280)
10. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-64
11. Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996;348:370-4 (Pubitemid 26261511)
12. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-23 (Pubitemid 28152883)
13. Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results. J Vasc Surg 1998;28:964-5
14. Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: A double-blind randomized trial. Hum Gene Ther 2006;17:683-91 (Pubitemid 43970708)
15. Rajagopalan S, Mohler ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, doubleblind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003;108:1933-8 (Pubitemid 37296537)
16. Muona K, Makinen K, Hedman M, et al. 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Ther 2012;19:392-5
17. Comerota AJ, Throm RC, Miller KA, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: Preliminary results of a phase I trial. J Vasc Surg 2002;35:930-6 (Pubitemid 44718562)
18. Nikol S, Baumgartner I, Van Belle E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008;16:972-8 (Pubitemid 351587109)
19. Belch J, Hiatt WR, Baumgartner I, et al. Effect of fibroblast growth factor NV1FGF on amputation and death: A randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011;377:1929-37
20. Baumgartner I, Chronos N, Comerota A, et al. Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia. Mol Ther 2009;17:914-21
21. Shigematsu H, Yasuda K, Iwai T, et al. Randomized, double-blind, placebocontrolled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010;17:1152-61
22. Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci 2010;86:588-610
23. Kaga T, Kawano H, Sakaguchi M, et al. Hepatocyte growth factor stimulated angiogenesis without inflammation: Differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor. Vascul Pharmacol 2012;57:3-9
24. Morishita R, Nakamura S, Hayashi S, et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999;33:1379-84 (Pubitemid 29282658)
25. Hayashi S, Morishita R, Nakamura S, et al. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: Downregulation of HGF in response to hypoxia in vascular cells. Circulation 1999;100:II301-8 (Pubitemid 29523551)
26. Taniyama Y, Morishita R, Hiraoka K, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: Molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001;104:2344-50 (Pubitemid 33049519)
27. Taniyama Y, Morishita R, Aoki M, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: Preclinical study for treatment of peripheral arterial disease. Gene Ther 2001;8:181-9 (Pubitemid 32186129)
28. Hiraoka K, Koike H, Yamamoto S, et al. Enhanced therapeutic angiogenesis by cotransfection of prostacyclin synthase gene or optimization of intramuscular injection of naked plasmid DNA. Circulation 2003;108:2689-96 (Pubitemid 37466812)
29. Koike H, Morishita R, Iguchi S, et al. Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene. FASEB J 2003;17:779-81
30. Matsuki A, Yamamoto S, Nakagami H, et al. No influence of tumor growth by intramuscular injection of hepatocyte growth factor plasmid DNA: Safety evaluation of therapeutic angiogenesis gene therapy in mice. Biochem Biophys Res Commun 2004;315:59-65 (Pubitemid 38175185)
31. Morishita R, Makino H, Aoki M, et al. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol 2011;31:713-20
32. Makino H, Aoki M, Hashiya N, et al. Long-Term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler Thromb Vasc Biol 2012;32:2503-9
33. Powell RJ, Simons M, Mendelsohn FO, et al. Results of a double-blind, placebocontrolled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008;118:58-65
34. Powell RJ, Goodney P, Mendelsohn FO, et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: Results of the HGF-0205 trial. J Vasc Surg 2010;52:1525-30
35. Henry TD, Hirsch AT, Goldman J, et al. Safety of a non-viral plasmidencoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: A phase I study. Gene Ther 2011;18:788-94
36. Saeed M, Martin A, Ursell P, et al. MR assessment of myocardial perfusion, viability, and function after intramyocardial transfer of VM202, a new plasmid human hepatocyte growth factor in ischemic swine myocardium. Radiology 2008;249:107-18
37. Ajroud-Driss S, Christiansen M, Allen JA, et al. Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy. Mol Ther 2013;21:1279-86
38. Grines CL, Watkins MW, Helmer G, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7 (Pubitemid 34260418)
39. Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003;42:1339-47 (Pubitemid 37267270)
40. Rajagopalan S, Olin J, Deitcher S, et al. Use of a constitutively active hypoxiainducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: Phase I doseescalation experience. Circulation 2007;115:1234-43 (Pubitemid 46594767)
41. Tachibana K, Tachibana S. Albumin microbubble echo-contrast material as an enhancer for ultrasound accelerated thrombolysis. Circulation 1995;92:1148-50
42. Bao S, Thrall BD, Miller DL. Transfection of a reporter plasmid into cultured cells by sonoporation in vitro. Ultrasound Med Biol 1997;23:953-9 (Pubitemid 27349543)
43. Shohet R V, Chen S, Zhou YT, et al. Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation 2000;101:2554-6 (Pubitemid 30350631)
44. Taniyama Y, Tachibana K, Hiraoka K, et al. Development of safe and efficient novel nonviral gene transfer using ultrasound: Enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther 2002;9:372-80 (Pubitemid 34414035)
45. Taniyama Y, Tachibana K, Hiraoka K, et al. Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation 2002;105:1233-9 (Pubitemid 34225826)
46. Shimamura M, Sato N, Taniyama Y, et al. Gene transfer into adult rat spinal cord using naked plasmid DNA and ultrasound microbubbles. J Gene Med 2005;7:1468-74 (Pubitemid 41672405)
47. Endoh M, Koibuchi N, Sato M, et al. Fetal gene transfer by intrauterine injection with microbubble-enhanced ultrasound. Mol Ther 2002;5:501-8 (Pubitemid 34546079)
48. Suzuki G. Recent progress in plant reproduction research: The story of the male gametophyte through to successful fertilization. Plant Cell Physiol 2009;50:1857-64
49. Unger EC, Hersh E, Vannan M, et al. Local drug and gene delivery through microbubbles. Prog Cardiovasc Dis 2001;44:45-54 (Pubitemid 32807854)
50. Kudo N, Okada K, Yamamoto K. Sonoporation by single-shot pulsed ultrasound with microbubbles adjacent to cells. Biophys J 2009;96:4866-76
51. Li T, Tachibana K, Kuroki M, et al. Gene transfer with echo-enhanced contrast agents: Comparison between Albunex, Optison, and Levovist in mice-initial results. Radiology 2003;229:423-8 (Pubitemid 37310829)
52. Juffermans LJM, Dijkmans PA, Musters RJP, et al. Transient permeabilization of cell membranes by ultrasound-exposed microbubbles is related to formation of hydrogen peroxide. Am J Physiol Heart Circ Physiol 2006;291:H1595-601 (Pubitemid 44497663)
53. Mukherjee D, Wong J, Griffin B, et al. Ten-fold augmentation of endothelial uptake of vascular endothelial growth factor with ultrasound after systemic administration. J Am Coll Cardiol 2000;35:1678-86 (Pubitemid 30307516)
54. Cui Z, Baizer L, Mumper RJ. Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. J Biotechnol 2003;102:105-15 (Pubitemid 36412155)
55. Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nat Rev Drug Discov 2006;5:543-8 (Pubitemid 43971188)
56. Kunugiza Y, Tomita N, Taniyama Y, et al. Acceleration of wound healing by combined gene transfer of hepatocyte growth factor and prostacyclin synthase with Shima Jet. Gene Ther 2006;13:1143-52 (Pubitemid 44084073)
57. Sawamura D, Ina S, Itai K, et al. In vivo gene introduction into keratinocytes using jet injection. Gene Ther 1999;6:1785-7 (Pubitemid 29485956)
58. Nakagawa A, Makino H, Aoki M, et al. Improvement of survival of skin flaps by combined gene transfer of hepatocyte growth factor and prostacyclin synthase. J Gene Med 2007;9:1087-94 (Pubitemid 350286414)
59. Walther W, Siegel R, Kobelt D, et al. Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer. Clin Cancer Res 2008;14:7545-53
60. Walther W, Stein U, Fichtner I, et al. Intratumoral low-volume jet-injection for efficient nonviral gene transfer. Mol Biotechnol 2002;21:105-15 (Pubitemid 34521609)
61. Walther W, Stein U, Fichtner I, et al. Nonviral in vivo gene delivery into tumors using a novel low volume jet-injection technology. Gene Ther 2001;8:173-80 (Pubitemid 32186128)
62. Choi AH-C, Smiley K, Basu M, et al. Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needlefree injection. Vaccine 2007;25:3215-18 (Pubitemid 46482753)
63. Hallermalm K, Johansson S, Bra°ve A, et al. Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer. Scand J Immunol 2007;66:43-51 (Pubitemid 46985511)
64. Soboll G, Hussey SB, Whalley JM, et al. Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies. Vet Immunol Immunopathol 2006;111:81-95
65. Degano P, Sarphie DF, Bangham CR. Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system. Vaccine 1998;16:394-8 (Pubitemid 28010776)
66. Tacket CO, Roy MJ, Widera G, et al. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 1999;17:2826-9 (Pubitemid 29323008)
67. Breathnach CC, Rudersdorf R, Lunn DP. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Vet Immunol Immunopathol 2004;98:127-36 (Pubitemid 38317026)
68. Wolff JA, Williams P, Acsadi G, et al. Conditions affecting direct gene transfer into rodent muscle in vivo. Biotechniques 1991;11:474-85
69. Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease Meta-Analysis and systematic review of the literature. Atherosclerosis 2010;209:10-17
70. Benoit E, O'Donnell TF, Patel AN. Safety and efficacy of autologous cell therapy in critical limb ischemia: A systematic review. Cell Transplant 2013;22:545-62
71. Teraa M, Sprengers RW, van der Graaf Y, et al. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: A meta-Analysis of randomized controlled clinical trials. Ann Surg 2013;258:922-9
72. Losordo DW, Kibbe MR, Mendelsohn F, et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv 2012;5:821-30
73. Jarajapu YPR, Caballero S, Verma A, et al. Blockade of NADPH oxidase restores vasoreparative function in diabetic CD34+ cells. Invest Ophthalmol Vis Sci 2011;52:5093-104
74. Chen F, Tan Z, Dong CY, et al. Combination of VEGF(165)/ Angiopoietin-1 gene and endothelial progenitor cells for therapeutic neovascularization. Eur J Pharmacol 2007;568:222-30 (Pubitemid 46976912)
75. Ymamoto Y, Matsuura T, Narasaki G, et al. Synergistic effects of autologous cell and hepatocyte growth factor gene therapy for neovascularization in a murine model of hindlimb ischemia. Am J Physiol Heart Circ Physiol 2009;297:H1329-36
76. Kobayashi K, Kondo T, Inoue N, et al. Combination of in vivo angiopoietin-1 gene transfer and autologous bone marrow cell implantation for functional therapeutic angiogenesis. Arterioscler Thromb Vasc Biol 2006;26:1465-72 (Pubitemid 44288970)
77. Fierro FA, Kalomoiris S, Sondergaard CS, et al. Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy. Stem Cells 2011;29:1727-37.